Hydrogenology
Hydrogenology editorial study record

Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid arthritis: a randomized, double-blind, placebo-controlled pilot study

Ishibashi T et al. · Int Immunopharmacol. 2014;21(2):468–473.

HumanH₂-rich waterPublished 2014
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized double-blind placebo-controlled pilot trial

Research topic

Immune and inflammatory conditions

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults with rheumatoid arthritis

Sample

24 participants: H₂ saline n=12; placebo saline n=12

Duration

Daily for 5 days; follow-up through 4 weeks

Intervention

500 mL H₂-dissolved saline by intravenous drip daily

Hydrogen form

H₂ dissolved in intravenous saline — not inhaled, not H₂-rich drinking water and not Brown’s gas.

H₂ specification

1 ppm dissolved H₂.

H₂ flow

Not applicable — intravenous infusion, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

500 mL placebo saline by intravenous drip

Reported, not endorsed

Outcomes and reported result

Outcomes measured

DAS28, IL-6, TNF-α, MMP-3 and urinary 8-OHdG

Reported result

DAS28 and several laboratory markers favored H₂ saline at four weeks; TNF-α did not change meaningfully. The sample was very small.

Results-extraction completeness

Abstract and licensed full-text copy checked for methods and principal results; independent appraisal and complete conflict extraction remain incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Twenty-four-person pilot, five-day intervention and mainly disease-score and biomarker outcomes. Financial support was reported as none; complete author-industry relationship extraction remains pending.

Applies directly to

Adults with rheumatoid arthritis under supervised intravenous infusion; it does not inform drinking or inhalation protocols.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 24929023 · DOI: 10.1016/j.intimp.2014.06.001

Publisher access

The publisher identifies the article as open access under a Creative Commons license; a free full-text copy is available on ResearchGate.

Extraction basis

Licensed author-uploaded full text, publisher abstract and PubMed record.

Record revision

2026-08-10